Orchestra BioMed Holdings (OBIO) AI Stock Analysis

• Market Cap: $263.93M
• Dividend Yield: N/A
• Average Volume (3M): 200.79K
• Price to Earnings (P/E): 6.6
• Beta (1Y): 1.97
• Revenue Growth: 6.46%
• EPS Growth: -14.32%
• Country: US
• Employees: 70
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.12
• Shares Outstanding: 58,520,900
• 10 Day Avg. Volume: 266,210
• 30 Day Avg. Volume: 200,786
• PEG Ratio: 90.81
• Price to Book (P/B): 2.51K
• Price to Sales (P/S): 4758.67
• P/FCF Ratio: -3.22K
• Enterprise Value/Market Cap: 0.94
• Enterprise Value/Revenue: 7.40
• Enterprise Value/Gross Profit: 7.44
• Enterprise Value/Ebitda: -4.83
• 1Y Price Target: $13.40
• Price Target Upside: 190.67% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): -1.69
• Revenue Forecast (FY): $1.08M

• Rating: 52 Neutral
• Price Target: $4.50 ▼(-2.39% Downside)
• Action: Reiterated Date: 03/12/26
• Date: Action: Reiterated 03/12/26

The score is held back primarily by heavy ongoing losses and significant cash burn despite strong gross margins and a recent revenue inflection. Technicals are supportive with price above major moving averages and positive momentum indicators, while valuation remains constrained by negative earnings. Corporate events add some support via expected cash proceeds and execution-focused incentives.

Positive Factors

High-margin revenue step-up

A substantial TTM revenue increase alongside ~93% gross margin indicates the company is generating high-value, scalable revenue likely tied to device/partnership economics. High gross margins support durable unit economics and provide a foundation for future operating leverage if fixed costs are absorbed as revenue scales.

Partnership-driven business model

Validated collaborations and sizable strategic capital commitments de-risk development and commercial pathways. Partnerships can supply regulatory, distribution and co-funding support, accelerating pivotal trials and reducing need for sole in-house commercialization spend, strengthening long-term execution capacity.

Conservative leverage and equity base

Modest absolute debt and a healthy equity cushion give the company financial flexibility to fund clinical programs and pursue strategic deals. Low leverage reduces bankruptcy risk and preserves capacity to raise debt or negotiate partnership terms, important for multi-year device development cycles.

Negative Factors

Sustained cash burn

Persistent negative operating and free cash flow near -$49M TTM means the business is not self-funding. Continued cash burn requires recurring external financing, raising dilution risk and creating dependency on capital markets or partners to sustain pivotal trials and commercialization efforts over the medium term.

Large operating losses

Despite revenue gains, heavy operating losses show the company has not yet translated high gross margins into profitability. Extended negative EBIT and net margins increase the time and scale required to reach break-even, pressuring returns on invested capital and elevating execution risk for long-term investors.

Reliance on milestone proceeds

Material near-term proceeds tied to the Vivasure sale and future earnouts create funding dependency on milestone realization. Such one-time or contingent cash inflows are uncertain and, if delayed or reduced, could force dilutive financings or slow trial timelines, increasing structural liquidity and execution risk.

Orchestra BioMed Holdings Business Overview & Revenue Model

Company Description

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

How the Company Makes Money

null

Orchestra BioMed Holdings Financial Statement Overview

Summary

Despite a sharp TTM revenue step-up (~$33.5M) and very high gross margin (~93%), results remain dominated by large operating losses (EBIT about -$51.8M TTM) and sustained cash burn (operating/FCF around -$49M TTM). Low debt (~$1.7M) and positive equity (~$53.6M) help, but liquidity runway/dilution risk persists without loss narrowing.

Income Statement

TTM (Trailing-Twelve-Months) revenue surged to ~$33.5M (very strong growth versus prior periods), and gross margin remains high (~93%), suggesting the revenue base is high-value. However, profitability is still a clear weakness: operating losses remain heavy (EBIT about -$51.8M TTM) with deeply negative net margins, and losses have persisted across all reported periods despite the recent top-line step-up.

Balance Sheet

The balance sheet shows modest leverage with low absolute debt (~$1.7M TTM) and positive equity (~$53.6M), which provides financial flexibility. Total assets are sizable (~$114.9M). The key concern is that returns on equity remain materially negative due to ongoing net losses, meaning the capital base is not yet translating into shareholder value creation.

Cash Flow

Cash generation remains a major pressure point: operating cash flow and free cash flow are both around -$49M TTM, and free cash flow has continued to deteriorate versus the prior year. While free cash flow roughly tracks net losses (cash burn broadly consistent with reported losses), the business is still far from self-funding and likely reliant on external capital until operating performance improves.

Breakdown	Dec 2025	Mar 2025	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	33.48M	2.64M	2.76M	3.53M	-782.00K
Gross Profit	33.29M	2.43M	2.57M	3.21M	-981.00K
EBITDA	-51.48M	-63.99M	-51.22M	-32.44M	-21.62M
Net Income	-52.95M	-61.02M	-49.12M	-33.61M	-23.01M
Balance Sheet
Total Assets	114.86M	76.17M	95.21M	95.57M	13.53M
Cash, Cash Equivalents and Short-Term Investments	106.51M	66.81M	87.59M	83.78M	10.90M
Total Debt	1.69M	16.53M	1.69M	11.87M	5.67M
Total Liabilities	51.48M	43.22M	27.17M	43.04M	84.76M
Stockholders Equity	63.38M	32.96M	68.04M	52.53M	-71.23M
Cash Flow
Free Cash Flow	-49.45M	-50.85M	-46.20M	-29.88M	-19.70M
Operating Cash Flow	-48.96M	-50.56M	-46.13M	-29.29M	-19.43M
Investing Cash Flow	-26.94M	13.09M	10.69M	-64.12M	13.02M
Financing Cash Flow	88.33M	29.17M	46.22M	103.26M	-3.99M

Orchestra BioMed Holdings Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.61
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OBIO, the sentiment is Positive. The current price of 4.61 is above the 20-day moving average (MA) of 4.37, above the 50-day MA of 4.22, and above the 200-day MA of 3.58, indicating a bullish trend. The MACD of 0.11 indicates Negative momentum. The RSI at 54.87 is Neutral, neither overbought nor oversold. The STOCH value of 58.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for OBIO.

Orchestra BioMed Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CLYM	61 Neutral	$340.11M	-4.53	-33.41%	―	―	64.81%
OBIO	52 Neutral	$263.93M	6.65	-170.45%	―	6.46%	-14.32%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CGTX	47 Neutral	$97.10M	-5.34	-109.73%	―	―	50.39%
CRDF	45 Neutral	$123.74M	-4.09	-82.00%	―	-27.29%	16.40%
PYXS	45 Neutral	$95.26M	-1.58	-87.28%	―	-82.53%	-52.00%

Orchestra BioMed Holdings Corporate Events

Orchestra BioMed Adopts 2026 Performance-Driven Executive Compensation Plan

On February 12, 2026, Orchestra BioMed Holdings, Inc.’s board of directors approved a 2026 cash bonus plan for its executive officers that ties payouts to mid-year and full-year performance against clinical, financial, and operational goals, including key enrollment and milestone targets in its BACKBEAT and Virtue SAB pivotal studies. The board also adopted difficult stretch goals linked to study enrollment, partnership expansion, and additional metrics, revised the vesting schedule for restricted stock units to a three-year, four-tranche structure, and raised base salaries and target bonus percentages for the CEO and president/COO, signaling a stronger, performance-driven compensation framework aligned with the company’s pipeline execution and growth objectives.

On February 12, 2026, the board further set 2026 objectives and stretch goals that will determine executive bonuses, with the CEO and president/COO bonuses fully tied to these company-wide targets and the CFO’s bonus also influenced by individual performance criteria. These changes, including increased variable compensation and updated equity vesting, are likely aimed at enhancing retention and aligning leadership incentives with long-term clinical and financial milestones that are critical for the company’s competitive positioning in cardiovascular medical devices.

The most recent analyst rating on (OBIO) stock is a Sell with a $3.50 price target. To see the full list of analyst forecasts on Orchestra BioMed Holdings stock, see the OBIO Stock Forecast page.

Orchestra BioMed gains cash from Vivasure sale proceeds

On January 12, 2026, Orchestra BioMed announced it expects to receive up to $21 million in cash proceeds following the January 9, 2026 closing of Haemonetics Corporation’s acquisition of its long-held strategic investment Vivasure Medical, an Ireland-based developer of bioabsorbable, large-bore percutaneous vessel closure technology. Orchestra BioMed anticipates $11 million of this amount will be realized in 2026 through an upfront payment of about $5 million and a first milestone payment of about $6 million, with additional consideration tied to future revenue earnouts, underscoring the financial value and strategic validation of its partnership-driven device development model and strengthening its position as an innovation partner to larger medtech players.

The most recent analyst rating on (OBIO) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Orchestra BioMed Holdings stock, see the OBIO Stock Forecast page.